Jennifer Regan - 29 May 2024 Form 4 Insider Report for Accelerate Diagnostics, Inc (AXDX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
30 May 2024, 16:25:38 UTC
Prior SEC filing
21 May 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ David Patience, attorney-in-fact

Key filing fact

Jennifer Regan filed Form 4 for Accelerate Diagnostics, Inc (AXDX) on 30 May 2024.

Key facts

  • This page summarizes Jennifer Regan's Form 4 filing for Accelerate Diagnostics, Inc (AXDX).
  • 4 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 30 May 2024, 16:25.

Change

  • Previous filing in this sequence was filed on 21 May 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AXDX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+7,894
Change %
Price
$0.000000
Shares after
7,894
Date
29 May 2024
Ownership
Direct
Footnotes
F1
AXDX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+4,737
Change %
+60%
Price
$0.000000
Shares after
12,631
Date
29 May 2024
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXDX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-7,894
Change %
-100%
Price
$0.000000*
Shares after
0
Date
29 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,894
Exercise price
Footnotes
F1, F2
AXDX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-4,737
Change %
-20%
Price
$0.000000
Shares after
18,947
Date
29 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,737
Exercise price
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.

Footnote F2

On May 29, 2023, the reporting person was granted a total of 7,894 RSUs, which vested on the first-year anniversary of the grant date.

Footnote F3

On May 29, 2023, the reporting person was granted a total of 23,684 RSUs, which vest in five equal annual installments beginning on May 29, 2024.

SEC remarks

On July 11, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-10 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares of the issuer's common stock underlying its outstanding equity awards, warrants and convertible notes, as well as the exercise or conversion price, as applicable. The amounts reported after the effective date of the Reverse Stock Split, including the amounts reported herein (and to be reported in subsequent reports), have been adjusted to reflect the Reverse Stock Split.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .